טוען...
Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
Pancreatic cancer remains a clinical challenge, thus new therapies are urgently needed. The selective Wee1 inhibitor MK-1775 has demonstrated promising results when combined with DNA damaging agents, and more recently with CHK1 inhibitors in various malignancies. We have previously demonstrated that...
שמור ב:
| הוצא לאור ב: | Cancer Lett |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4282784/ https://ncbi.nlm.nih.gov/pubmed/25458954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2014.10.015 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|